Literature DB >> 20590613

Induction of apoptosis by the ginsenoside Rh2 by internalization of lipid rafts and caveolae and inactivation of Akt.

E-K Park1, E J Lee, S-H Lee, K H Koo, J Y Sung, E H Hwang, J H Park, C-W Kim, K-C Jeong, B-K Park, Y-N Kim.   

Abstract

BACKGROUND AND
PURPOSE: Lipid rafts and caveolae are membrane microdomains with important roles in cell survival signalling involving the Akt pathway. Cholesterol is important for the structure and function of these microdomains. The ginsenoside Rh2 exhibits anti-tumour activity. Because Rh2 is structurally similar to cholesterol, we investigated the possibility that Rh2 exerted its anti-tumour effect by modulating rafts and caveolae. EXPERIMENTAL APPROACH: A431 cells (human epidermoid carcinoma cell line) were treated with Rh2 and the effects on cell apoptosis, raft localization and Akt activation measured. We also examined the effects of over-expression of Akt and active-Akt on Rh2-induced cell death. KEY
RESULTS: Rh2 induced apoptosis concentration- and time-dependently. Rh2 reduced the levels of rafts and caveolae in the plasma membrane and increased their internalization. Furthermore, Akt activity was decreased and consequently, Akt-dependent phosphorylation of Bad, a pro-survival protein, was decreased whereas the pro-apoptotic proteins, Bim and Bax, were increased upon Rh2 treatment. Unlike microdomain internalization induce by cholesterol depletion, Rh2-mediated internalization of rafts and caveolae was not reversed by cholesterol addition. Also, cholesterol addition did not restore Akt activation or rescue cells from Rh2-induced cell death. Rh2-induced cell death was attenuated in MDA-MB-231 cells over-expressing either wild-type or dominant-active Akt. CONCLUSIONS AND IMPLICATIONS: Rh2 induced internalization of rafts and caveolae, leading to Akt inactivation, and ultimately apoptosis. Because elevated levels of membrane rafts and caveolae, and Akt activation have been correlated with cancer development, internalization of these microdomains by Rh2 could potentially be used as an anti-cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20590613      PMCID: PMC2936029          DOI: 10.1111/j.1476-5381.2010.00768.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  32 in total

Review 1.  Lipid rafts: contentious only from simplistic standpoints.

Authors:  John F Hancock
Journal:  Nat Rev Mol Cell Biol       Date:  2006-06       Impact factor: 94.444

2.  Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts.

Authors:  Liyan Zhuang; Jayoung Kim; Rosalyn M Adam; Keith R Solomon; Michael R Freeman
Journal:  J Clin Invest       Date:  2005-03-17       Impact factor: 14.808

3.  Akt inhibition upregulates FasL, downregulates c-FLIPs and induces caspase-8-dependent cell death in Jurkat T lymphocytes.

Authors:  S M Uriarte; S Joshi-Barve; Z Song; R Sahoo; L Gobejishvili; V R Jala; B Haribabu; C McClain; S Barve
Journal:  Cell Death Differ       Date:  2005-03       Impact factor: 15.828

Review 4.  Lipid rafts: heterogeneity on the high seas.

Authors:  Linda J Pike
Journal:  Biochem J       Date:  2004-03-01       Impact factor: 3.857

5.  Cholesterol depletion induces anoikis-like apoptosis via FAK down-regulation and caveolae internalization.

Authors:  Eun-Kyung Park; Mi Jung Park; Seong-Hee Lee; Ying Chun Li; Jungeun Kim; Jae-Seon Lee; Jung Weon Lee; Sang-Kyu Ye; Jong-Wan Park; Chul-Woo Kim; Byung-Kiu Park; Yong-Nyun Kim
Journal:  J Pathol       Date:  2009-07       Impact factor: 7.996

6.  Inhibitory effects by oral administration of ginsenoside Rh2 on the growth of human ovarian cancer cells in nude mice.

Authors:  T Tode; Y Kikuchi; T Kita; J Hirata; E Imaizumi; I Nagata
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

Review 7.  Dissecting lipid raft facilitated cell signaling pathways in cancer.

Authors:  Samir Kumar Patra
Journal:  Biochim Biophys Acta       Date:  2007-12-05

8.  Epidermal growth factor-stimulated tyrosine phosphorylation of caveolin-1. Enhanced caveolin-1 tyrosine phosphorylation following aberrant epidermal growth factor receptor status.

Authors:  Y N Kim; G J Wiepz; A G Guadarrama; P J Bertics
Journal:  J Biol Chem       Date:  2000-03-17       Impact factor: 5.157

9.  Cholesterol sensitivity of endogenous and myristoylated Akt.

Authors:  Rosalyn M Adam; Nishit K Mukhopadhyay; Jayoung Kim; Dolores Di Vizio; Bekir Cinar; Kelly Boucher; Keith R Solomon; Michael R Freeman
Journal:  Cancer Res       Date:  2007-07-01       Impact factor: 12.701

10.  Inhibitory effects of ginsenoside Rh2 on tumor growth in nude mice bearing human ovarian cancer cells.

Authors:  H Nakata; Y Kikuchi; T Tode; J Hirata; T Kita; K Ishii; K Kudoh; I Nagata; N Shinomiya
Journal:  Jpn J Cancer Res       Date:  1998-07
View more
  22 in total

Review 1.  Annexins as organizers of cholesterol- and sphingomyelin-enriched membrane microdomains in Niemann-Pick type C disease.

Authors:  Magdalena Domon; Mehmet Nail Nasir; Gladys Matar; Slawomir Pikula; Françoise Besson; Joanna Bandorowicz-Pikula
Journal:  Cell Mol Life Sci       Date:  2011-12-13       Impact factor: 9.261

2.  Glycyrrhetic acid synergistically enhances β₂-adrenergic receptor-Gs signaling by changing the location of Gαs in lipid rafts.

Authors:  Qian Shi; Yuanyuan Hou; Jie Hou; Penwei Pan; Ze Liu; Min Jiang; Jie Gao; Gang Bai
Journal:  PLoS One       Date:  2012-09-27       Impact factor: 3.240

3.  Ginsenosides as Anticancer Agents: In vitro and in vivo Activities, Structure-Activity Relationships, and Molecular Mechanisms of Action.

Authors:  Subhasree Ashok Nag; Jiang-Jiang Qin; Wei Wang; Ming-Hai Wang; Hui Wang; Ruiwen Zhang
Journal:  Front Pharmacol       Date:  2012-02-28       Impact factor: 5.810

4.  Neutral sphingomyelinase 2 modulates cytotoxic effects of protopanaxadiol on different human cancer cells.

Authors:  Bonggoo Park; Yong-Moon Lee; Jae-Sung Kim; Youl Her; Ju Hee Kang; Seung-Hyun Oh; Hwan-Mook Kim
Journal:  BMC Complement Altern Med       Date:  2013-07-27       Impact factor: 3.659

5.  The apoptotic effect of D Rhamnose β-hederin, a novel oleanane-type triterpenoid saponin on breast cancer cells.

Authors:  Lin Cheng; Tian-Song Xia; Yi-Fen Wang; Wenbin Zhou; Xiu-Qing Liang; Jin-Qiu Xue; Liang Shi; Ying Wang; Qiang Ding
Journal:  PLoS One       Date:  2014-03-06       Impact factor: 3.240

6.  Ginsenoside Rh2 inhibits human A172 glioma cell proliferation and induces cell cycle arrest status via modulating Akt signaling pathway.

Authors:  Kai-Fei Li; Chun-Min Kang; Xiao-Feng Yin; Hai-Xia Li; Zhuo-Yu Chen; Yao Li; Qiong Zhang; Yu-Rong Qiu
Journal:  Mol Med Rep       Date:  2017-12-05       Impact factor: 2.952

7.  In Vitro Synergistic Inhibition of HT-29 Proliferation and 2H-11 and HUVEC Tubulogenesis by Bacopaside I and II Is Associated with Ca2+ Flux and Loss of Plasma Membrane Integrity.

Authors:  Yoko Tomita; Eric Smith; Helen M Palethorpe; Maryam Nakhjavani; Kenny K L Yeo; Amanda R Townsend; Timothy J Price; Andrea J Yool; Jennifer E Hardingham
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-06

8.  Cardioprotective Effects of 20(S)-Ginsenoside Rh2 against Doxorubicin-Induced Cardiotoxicity In Vitro and In Vivo.

Authors:  Hongbo Wang; Pengfei Yu; Haitao Gou; Jianqiao Zhang; Mei Zhu; Zhen-Hua Wang; Jing-Wei Tian; Yong-Tao Jiang; Feng-Hua Fu
Journal:  Evid Based Complement Alternat Med       Date:  2012-10-17       Impact factor: 2.629

9.  Ginsenoside compound K induces apoptosis in nasopharyngeal carcinoma cells via activation of apoptosis-inducing factor.

Authors:  Carmen Ka-Man Law; Hoi-Hin Kwok; Po-Ying Poon; Chi-Chiu Lau; Zhi-Hong Jiang; William Chi-Shing Tai; Wendy Wen-Luan Hsiao; Nai-Ki Mak; Patrick Ying-Kit Yue; Ricky Ngok-Shun Wong
Journal:  Chin Med       Date:  2014-04-02       Impact factor: 5.455

10.  New generation of drug delivery systems based on ginsenoside Rh2-, Lysine- and Arginine-treated highly porous graphene for improving anticancer activity.

Authors:  Hadi Zare-Zardini; Asghar Taheri-Kafrani; Ahmad Amiri; Abdol-Khalegh Bordbar
Journal:  Sci Rep       Date:  2018-01-12       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.